Member Info for sajy

Iain has said they expect to sign deals this year. It all depends on how lucrative those deals are, if we can get a decent upfront payment of around £10 - 20 Million then can see the SP back at 40/50p.

Dilution not ideal, but had to in order to get the deal over the line. The following news flow is what I am expecting.
1. Sporcov update, which is well overdue.
2. Update on pre-clinical trials for XF-73 for USA (treating wounds)
3. Licensing for XF-73. Expecting a major pharma as partner and expecting the figures to dwarf the M3 deal.

DO SOME OF YOU KNOW WHAT YOU TALKING ABOUT?
It is only 20 Million shares NOT 200 Million. Not massive dilution as you say.

Further director buys as stated and won't be the last.

Talk on ADVFN of a placing. Not sure myself if any truth in it, but judging by the share price action, could be true.

Must admit it is taking a lot longer than I envisaged. I expected the deal to be announced by now. My understanding was that as part of the deal, the partner would be investing in Dest. Could it be that what is holding the deal up, as the share price has risen from 32p up to 60p and they have to agree at what price to invest at. Just my thoughts.

Iain in action

https://t.co/IjCYFVxrla

1. No trading update issued in Jan as one was issued in December.
2. The Chad production reported in the update in December is the latest public figure Savannah has released.
3. South Sudan acquisition. Guidance for deal completion remains H1 2023. Savannah will update the market as appropriate should this change.

https://t.co/JULQxqIOCx

Hi pjmcgra, I stopped posting on Polx chat board as I didn't want to waste my time with a few idiots on that board. All I ever tried to do was provide info to help people on that board. As you can see most of what I suggested was true in the end.

You could be right Candid, but my research suggests otherwise. Lets wait and see, announcement must be any day now.

As I have stated before my research has led me to believe that our partner for M3 will be a medium size pharma and not a large pharma. The Mcap is likely to be under a Billion dollars. However I do expect our partner for XF-73 to be a Major pharma, as I expect XF-73 to become a blockbuster drug. Those are my thoughts and we will find out very soon.

Really, if that was the case then I would expect them to take part in the placing and not buying as they have. Also why would they do a placing when they cash runway into 2024. Do some research before posting absolute rubbish.

As suggested further director buys. Expect this to continue.

The rise this morning is due to Myles buying in and he has a large following. Also I am expecting further director buys, which should help.

All the evidence suggests that XF-73 will be a blockbuster drug. Partnering discussions were supposed to start in 2023 and we have had it confirmed that discussions started late 2022, earlier than expected. The US govt approaching Dest and paying for pre clinical trials for XF-73. Once pre clinical trials have met the endpoints I fully expect them to pay for clinical trials. All the reports in the media suggest governments are in desperate need for AMR drugs.

I think they will buy in these small amounts but often.

Looking forward to that and considering that a few small buys move the share price, could see some fireworks.

I am hoping the licensing deal announcement for M3 will be this week, fingers crossed.

LOL, I like your sense of humour Surprised.